OPK · Opko Health, Inc. · Webcasts, Transcripts & Audio
$1.48
-0.09 (-5.73%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$1.22B
Shares
746.33M
Volume · Oct 6
2.46M
Avg daily vol (3M)
3.32M
Opko Health, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Opko Health, Inc. (OPK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼53.4%
$179.74M
−$86.09M
'22 Q3
22-11-08
▼53.8%
$185.34M
−$85.23M
'22 Q4
23-02-23
▼27.8%
$237.58M
−$18.27M
'23 Q1
23-05-03
▼14.4%
$265.42M
−$19.64M
'23 Q2
23-08-03
▼0.6%
$178.59M
−$84.47M
'23 Q3
23-11-06
▼1.9%
$181.91M
−$66.48M
'23 Q4
24-02-27
▼26.9%
$173.69M
−$81.84M
'24 Q1
24-05-07
▼31.4%
$182.19M
−$10.30M
'24 Q2
24-08-07
▼2.8%
$173.63M
$24.89M
'24 Q3
24-11-07
▲1%
$183.64M
$14.03M
'24 Q4
25-02-27
▼13.7%
$149.95M
−$67.61M
'25 Q1
25-04-30
▼13.9%
$156.81M
−$148.44M
'25 Q2
25-07-31
▼12.6%
$151.67M
$21.63M
'25 Q3
25-10-29
▼19.2%
$148.45M
−$31.26M
'25 Q4
26-02-26
▼17.2%
$124.20M
−$54.85M
'26 Q1
26-04-28
LATEST
▲4.3%
$163.58M
−$8.42M
'26 Q2
26-07-27
Earnings call
FY26 · Q2
2026-07-27
Opko Health, Inc. (OPK) Q2 2026 Earnings Call Transcript
Positive tone
GLP-1/Glucagon and Metabolic Programs
NGENLA Commercial Performance with Pfizer
2026 Financial Guidance
Revenue
$163.58M
▲ 4.3% YoY Diluted EPS
$-0.01
Gross margin
48.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-28
Opko Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
Positive tone
Strategic partnerships
Diagnostics and BioReference
MODX pipeline progress
Revenue
$124.20M
▼ 17.2% YoY Diluted EPS
$-0.07
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Opko Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
Confident tone
ModeX multi-specific antibody pipeline
Merck-partnered EBV vaccine
Diagnostics / BioReference turnaround
Revenue
$148.45M
▼ 19.2% YoY Diluted EPS
$-0.04
▼ 500% YoY Gross margin
43.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Opko Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
Positive tone
ModeX pipeline and clinical programs
BARDA-funded COVID antibody
Regeneron collaboration
Revenue
$151.67M
▼ 12.6% YoY Diluted EPS
$0.03
▲ 0% YoY Gross margin
32.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Opko Health, Inc. (OPK) Q2 2025 Earnings Call Transcript
Positive tone
BioReference restructuring and Labcorp oncology sale
GLP-1/glucagon dual agonist (OPK-88006)
ModeX pipeline and EBV vaccine with Merck
Revenue
$156.81M
▼ 13.9% YoY Diluted EPS
$-0.19
Gross margin
31.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Opko Health, Inc. (OPK) Q1 2025 Earnings Call Transcript
Positive tone
BioReference divestiture and restructuring
NGENLA / Pfizer partnership
Pharmaceutical pipeline progress
Revenue
$149.95M
▼ 13.7% YoY Diluted EPS
$-0.10
Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Opko Health, Inc. (OPK) Q4 2024 Earnings Call Transcript
Confident tone
ModeX Pipeline and Multispecific Antibodies
BARDA Funding for Antiviral Programs
NGENLA Commercialization with Pfizer
Revenue
$183.64M
▲ 1% YoY Diluted EPS
$0.01
Gross margin
46.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Opko Health, Inc. (OPK) Q3 2024 Earnings Call Transcript
Positive tone
BioReference restructuring and profitability path
ModeX immuno-oncology pipeline
BARDA funding for multispecific antibodies
Revenue
$173.63M
▼ 2.8% YoY Diluted EPS
$0.03
Gross margin
23.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Opko Health, Inc. (OPK) Q2 2024 Earnings Call Transcript
Positive tone
BioReference Health Restructuring
NGENLA / Pfizer Partnership
ModeX Pipeline & Oncology Programs
Revenue
$182.19M
▼ 31.4% YoY Diluted EPS
$-0.01
Gross margin
28.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Opko Health, Inc. (OPK) Q1 2024 Earnings Call Transcript
Positive tone
NGENLA long-acting growth hormone launch
Pipeline development (oxyntomodulin, GLP-2, ModeX)
BioReference divestiture to LabCorp
Revenue
$173.69M
▼ 26.9% YoY Diluted EPS
$-0.12
Gross margin
24.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Opko Health, Inc. (OPK) Q4 2023 Earnings Call Transcript
Positive tone
NGENLA launch and growth hormone franchise
ModeX collaborations and pipeline
Diagnostics / BioReference turnaround
Revenue
$181.91M
▼ 1.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Opko Health, Inc. (OPK) Q3 2023 Earnings Call Transcript
Revenue
$178.59M
▼ 0.6% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Opko Health, Inc. (OPK) Q2 2023 Earnings Call Transcript
Revenue
$265.42M
▼ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Opko Health, Inc. (OPK) Q1 2023 Earnings Call Transcript
Revenue
$237.58M
▼ 27.8% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Opko Health, Inc. (OPK) Q4 2022 Earnings Call Transcript
Revenue
$185.34M
▼ 53.8% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Opko Health, Inc. (OPK) Q3 2022 Earnings Call Transcript
Revenue
$179.74M
▼ 53.4% YoY Diluted EPS
$-0.11
▼ 375% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Opko Health, Inc. (OPK) Q2 2022 Earnings Call Transcript
Revenue
$309.89M
▼ 30% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Opko Health, Inc. (OPK) Q1 2022 Earnings Call Transcript
Revenue
$329.22M
▼ 39.6% YoY Diluted EPS
$-0.08
▼ 260% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Opko Health, Inc. (OPK) Q4 2021 Earnings Call Transcript
Revenue
$401.33M
▼ 18.9% YoY Diluted EPS
$-0.11
▼ 320% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Opko Health, Inc. (OPK) Q3 2021 Earnings Call Transcript
Revenue
$385.81M
▼ 9.9% YoY Diluted EPS
$0.04
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Opko Health, Inc. (OPK) Q2 2021 Earnings Call Transcript
Revenue
$442.41M
▲ 46.9% YoY Diluted EPS
$-0.03
▼ 160% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Opko Health, Inc. (OPK) Q1 2021 Earnings Call Transcript
Revenue
$545.16M
▲ 157.8% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-18
Opko Health, Inc. (OPK) Q4 2020 Earnings Call Transcript
Revenue
$494.68M
▲ 120.5% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Opko Health, Inc. (OPK) Q3 2020 Earnings Call Transcript
Revenue
$428.06M
▲ 87.1% YoY Diluted EPS
$0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Opko Health, Inc. (OPK) Q2 2020 Earnings Call Transcript
Revenue
$301.21M
▲ 33.1% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Opko Health, Inc. (OPK) Q1 2020 Earnings Call Transcript
Revenue
$211.47M
▼ 4.9% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Opko Health, Inc. (OPK) Q4 2019 Earnings Call
Revenue
$224.34M
▲ 1.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts